Efficiency and safety of Neiyixiao combined with leuprorelin in patients with endometriosis
10.3760/cma.j.issn.1673-4246.2015.01.010
- VernacularTitle:自拟内异消方联合亮丙瑞林治疗子宫内膜异位症的有效性和安全性
- Author:
Yulan ZHANG
- Publication Type:Journal Article
- Keywords:
Endometriosis;
Leuprolide;
Drugs,Chinese herbal;
Neiyixiao
- From:
International Journal of Traditional Chinese Medicine
2015;(1):36-39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficiency and safety of self-made Neiyixiao decoction combined with leuprorelin in patients with endometriosis (EMs). Methods A total of 82 patients with EMs were randomly recruited into a treatment group and a control group, with 41 patients in each group. The treatment group was treated with self-made Neiyixiao decoction combined with leuprorelin, and the control group was treated with leuprorelin only. The serum levels of CA125 and RANTES were detected with enzyme-linked immunosorbent assay. The symptoms and signs scores for pelvic endometriosis were evaluated before and after the treatment. Results The symptoms scores (0.4 ± 0.2 vs. 0.6 ± 0.3;t=3.552, P=0.001) and the signs scores (0.8 ± 0.4 vs. 1.1 ± 0.6;t=2.664, P=0.009) for pelvic endometriosis after the treatment in the treatment group were significantly lower than those in the control group. The serum levels of CA125 (26.4 ± 11.9 U/ml vs. 33.9 ± 12.8 U/ml; t=2.012, P=0.048) and RANTES (34.3 ± 14.1 ng/L vs. 43.7 ± 16.8 ng/L;t=2.744, P=0.008) after the treatment in the treatment group were significantly lower than those in the control group. The total effective rate in the treatment group was significantly higher than that in the control group (90.2%vs. 73.2%;χ2=3.998, P=0.046), and the rate of adverse reaction significantly lower (7.3%vs. 24.4%;χ2=4.479, P=0.034). The recurrence rate in the treatment group was significantly lower than that in the control group (16.2%vs. 46.7%;χ2=5.954, P=0.015) during 12 months of follow-up. Conclusion Self-made Neiyixiao decoction combined with leuprorelin can decrease serum levels of CA125 and RANTES, alleviate symptoms and signs, and its efficiency and safety are superior to leuprorelin alone in patients with endometriosis.
